Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity.
暂无分享,去创建一个
T. Kensler | S. Sturla | L. Peterson | J. Gong | Xiang Yu | James F Neels
[1] Huiyun Liang,et al. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. , 2004, Molecular cancer therapeutics.
[2] E. Raymond,et al. Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells , 2004, Clinical Cancer Research.
[3] Xiang Yu,et al. NADPH Alkenal/One Oxidoreductase Activity Determines Sensitivity of Cancer Cells to the Chemotherapeutic Alkylating Agent Irofulven , 2004, Clinical Cancer Research.
[4] M. Kelner,et al. Synthesis and biological activity of enantiomers of antitumor irofulven. , 2004, The Journal of organic chemistry.
[5] D. Boger,et al. Mechanisms of in situ activation for DNA-targeting antitumor agents. , 2002, Chemical reviews.
[6] J. Woynarowski,et al. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). , 2000, Biochemical pharmacology.
[7] Kay M. Brummond,et al. A Rapid Synthesis of Hydroxymethylacylfulvene (HMAF) Using the Allenic Pauson−Khand Reaction. A Synthetic Approach to Either Enantiomer of This Illudane Structure , 2000 .
[8] J. Woynarowski,et al. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). , 1999, Biochemical pharmacology.
[9] Jianliang Lu,et al. A Short Synthesis of the Potent Antitumor Agent (±)-Hydroxymethylacylfulvene Using an Allenic Pauson-Khand Type Cycloaddition , 1999 .
[10] T. Mcmorris,et al. Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug. , 1999, Bioorganic & medicinal chemistry.
[11] S. Aaronson,et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. , 1995, Cancer research.
[12] M. Montoya,et al. Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. , 1995, Cancer research.
[13] T. Mcmorris,et al. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. , 1990, Journal of the National Cancer Institute.
[14] H. Eichholtz-Wirth,et al. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. , 1986, British Journal of Cancer.
[15] D. Dess,et al. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones , 1983 .
[16] M. Kelner,et al. Metabolism of antitumor acylfulvene by rat liver cytosol. , 1999, Biochemical pharmacology.
[17] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.